CD20 and CD3 Bispecific Target Combination (CD20/CD3)

CD20 is a multi-pass transmembrane protein encoded by the MS4A1 gene and expressed on most B cells. It is a key target for monoclonal antibody therapies in B cell malignancies and some autoimmune conditions. It may help regulate B cell activation and calcium signaling, but its precise physiological role remains partially unresolved[1][2][8]. CD3 refers to the multisubunit complex associated with the T-cell receptor on all T cells. It is essential for TCR-mediated signaling and T-cell activation. CD3-binding drugs can alter immune function and have been used both to activate and deplete T cells in various clinical settings[6][7]. "CD20/CD3" is a shorthand used in immunotherapy for bispecific antibodies that bind both CD20 (on B cells) and CD3 (on T cells), bringing T cells into close proximity to malignant B cells to trigger cytotoxic responses. There is no single molecule with this name; the terminology signifies a drug mechanism, not a molecular entity[1]. If you require information structured for a single canonical molecule or receptor, you must specify either "CD20" or "CD3"; "CD20/CD3" as a target is ambiguous and not formally correct.

Other names

B-lymphocyte antigen CD20MS4A1T-cell receptor CD3 complexCD3 complexCD20/CD3 bispecifics

CD20/CD3 bispecific antibodies function by simultaneously binding to CD20 on B cells and CD3 on T cells. This mechanism brings T cells into close proximity to malignant B cells, leading to the recruitment and activation of T cells via CD3 to trigger redirected cytotoxicity against CD20-expressing target cells.